Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295837267> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4295837267 endingPage "S1292" @default.
- W4295837267 startingPage "S1291" @default.
- W4295837267 abstract "Recently, a dual immunotherapy was approved in unresectable Malignant pleural mesothelioma (MPM). There is, however, no approved standard therapy for the treatment of early-stage MPM. A multimodal therapy, consisting of extended pleurectomy/decortication (eP/D) together with inductive or adjuvant chemotherapy is generally recommended. Considering the immunogenic effects of chemotherapy on the tumor microenvironment, synergistic effects are expected when such a treatment is combined with immune checkpoint inhibitor, as already shown by recent clinical data in patients with advanced MPM. The NICITA trial combines the above-mentioned considerations and assesses feasibility and efficacy of an innovative therapy consisting of adjuvant platinum-based chemotherapy with nivolumab in patients with MPM who have undergone surgical cytoreduction with eP/D. The NICITA trial (NCT04177953) is a randomized, open-label, phase II clinical trial that is conducted in 14 centers in Germany. Patients, diagnosed with MPM in stages I-III (UICC 8th edition) and epithelioid subtype, who have already undergone cytoreductive surgery by eP/D. Patients with hyperthermic intrathoracic chemoperfusion (HITOC) can be included. Patients are randomized 1:1 to receive either a combination of 4 cycles of pemetrexed/platinum-based adjuvant chemotherapy and nivolumab (480 mg q4w) followed by nivolumab maintenance therapy (12 cycles, 480 mg q4w) or 4 cycles of adjuvant chemotherapy only. Stratification takes place according to previous HITOC treatment (yes vs. no), performance status (ECOG 0,1 vs. 2), and achievement of macroscopic complete resection (yes vs. no). The primary endpoint is time-to-next-treatment. Secondary endpoints include progression-free survival, overall survival, measures of treatment-beyond-progression and quality of life, as well as the assessment of safety and tolerability. Furthermore, a comprehensive collection of biomarker samples, including tumor tissue, blood, and stool samples, for an accompanying translational research program is implemented. As of 30th April 2022, 63 of 92 planned patients have been enrolled into the NICITA trial. NCT04177953; EudraCT 2019-002466-13; AIO Study Number AIO-TRK/YMO-0419. Institute of Clinical Cancer Research (IKF) - Frankfurt, Germany. unrestricted grant from Bristol Myers Squibb GmbH & Co.KGaA (BMS)." @default.
- W4295837267 created "2022-09-15" @default.
- W4295837267 creator A5027809274 @default.
- W4295837267 date "2022-09-01" @default.
- W4295837267 modified "2023-10-16" @default.
- W4295837267 title "1641TiP Adjuvant nivolumab with chemotherapy in pleural mesothelioma: The NICITA trial" @default.
- W4295837267 doi "https://doi.org/10.1016/j.annonc.2022.07.1720" @default.
- W4295837267 hasPublicationYear "2022" @default.
- W4295837267 type Work @default.
- W4295837267 citedByCount "0" @default.
- W4295837267 crossrefType "journal-article" @default.
- W4295837267 hasAuthorship W4295837267A5027809274 @default.
- W4295837267 hasBestOaLocation W42958372671 @default.
- W4295837267 hasConcept C121608353 @default.
- W4295837267 hasConcept C126322002 @default.
- W4295837267 hasConcept C141071460 @default.
- W4295837267 hasConcept C142724271 @default.
- W4295837267 hasConcept C143998085 @default.
- W4295837267 hasConcept C203092338 @default.
- W4295837267 hasConcept C2776694085 @default.
- W4295837267 hasConcept C2777240266 @default.
- W4295837267 hasConcept C2777407522 @default.
- W4295837267 hasConcept C2777701055 @default.
- W4295837267 hasConcept C2777863537 @default.
- W4295837267 hasConcept C2777982462 @default.
- W4295837267 hasConcept C2778239845 @default.
- W4295837267 hasConcept C2779688492 @default.
- W4295837267 hasConcept C2780030458 @default.
- W4295837267 hasConcept C535046627 @default.
- W4295837267 hasConcept C71924100 @default.
- W4295837267 hasConceptScore W4295837267C121608353 @default.
- W4295837267 hasConceptScore W4295837267C126322002 @default.
- W4295837267 hasConceptScore W4295837267C141071460 @default.
- W4295837267 hasConceptScore W4295837267C142724271 @default.
- W4295837267 hasConceptScore W4295837267C143998085 @default.
- W4295837267 hasConceptScore W4295837267C203092338 @default.
- W4295837267 hasConceptScore W4295837267C2776694085 @default.
- W4295837267 hasConceptScore W4295837267C2777240266 @default.
- W4295837267 hasConceptScore W4295837267C2777407522 @default.
- W4295837267 hasConceptScore W4295837267C2777701055 @default.
- W4295837267 hasConceptScore W4295837267C2777863537 @default.
- W4295837267 hasConceptScore W4295837267C2777982462 @default.
- W4295837267 hasConceptScore W4295837267C2778239845 @default.
- W4295837267 hasConceptScore W4295837267C2779688492 @default.
- W4295837267 hasConceptScore W4295837267C2780030458 @default.
- W4295837267 hasConceptScore W4295837267C535046627 @default.
- W4295837267 hasConceptScore W4295837267C71924100 @default.
- W4295837267 hasLocation W42958372671 @default.
- W4295837267 hasOpenAccess W4295837267 @default.
- W4295837267 hasPrimaryLocation W42958372671 @default.
- W4295837267 hasRelatedWork W2168969668 @default.
- W4295837267 hasRelatedWork W2766695410 @default.
- W4295837267 hasRelatedWork W2768988395 @default.
- W4295837267 hasRelatedWork W3030905530 @default.
- W4295837267 hasRelatedWork W3042471957 @default.
- W4295837267 hasRelatedWork W3129950743 @default.
- W4295837267 hasRelatedWork W3136319535 @default.
- W4295837267 hasRelatedWork W4223442529 @default.
- W4295837267 hasRelatedWork W4254666574 @default.
- W4295837267 hasRelatedWork W4295837267 @default.
- W4295837267 hasVolume "33" @default.
- W4295837267 isParatext "false" @default.
- W4295837267 isRetracted "false" @default.
- W4295837267 workType "article" @default.